Challenges in the production and use of probiotics as therapeuticals in cancer treatment or prevention

Probiotics were defined as microbial strains that confer health benefits to their consumers. The concept has evolved during the last 20 years, and today metabolites produced by the strains, known as postbiotics, and even dead cells, known as paraprobiotics, are closely associated to them. The isolation of commensal strains from human microbiome has led to the development of next generation probiotics. This review aims to present an overview of the developments in the area of cancer prevention and treatment, intimately related to advances in the knowledge of the microbiome role in its genesis and therapy. Strain identification and characterization, production processes, delivery strategies, and clinical evaluation are crucial to translate results into the market with solid scientific support. Examples of recent tools in isolation, strain typification, quality control, and development of new probiotic strains are described. Probiotics market and regulation were originally developed in the food sector, but these new strategies will impact the pharmaceutical and health sectors, requiring new considerations in regulatory frameworks.

Automated summary

The concept of probiotics has evolved over the past 20 years to include postbiotics and paraprobiotics. The isolation of commensal strains from the human microbiome has led to the development of next-generation probiotics. Key factors such as strain identification, production processes, delivery strategies, and clinical evaluation are crucial for translating results into the market with solid scientific support.